A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.

Autor: Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Saini NY; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Cha SC; Toni Stephenson Lymphoma Center, Hematologic Malignancies Research Institute, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Wang Z; Toni Stephenson Lymphoma Center, Hematologic Malignancies Research Institute, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Stadtmauer EA; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Baladandayuthapani V; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and., Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and., Tross B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Honhar M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Rao SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Kim K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Popescu M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Szymura S; Toni Stephenson Lymphoma Center, Hematologic Malignancies Research Institute, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Zhang T; Toni Stephenson Lymphoma Center, Hematologic Malignancies Research Institute, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Anderson A; Toni Stephenson Lymphoma Center, Hematologic Malignancies Research Institute, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Levine BL; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Kerr N; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Garfall A; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Cohen A; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Vogl DT; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Dengel K; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., June CH; Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Champlin R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Kwak LW; Toni Stephenson Lymphoma Center, Hematologic Malignancies Research Institute, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

Publikováno v: Blood [Blood] 2022 Mar 03; Vol. 139 (9), pp. 1289-1301.

Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation

Autor: Qazilbash, M.H., Tross, B., Champlin, R.E., Cha, S.-c., Popescu, M., Shah, N., Bashir, Q., Patel, K., Kerr, N., Garfall, A., Cohen, A., Dengel, K., June, C., Stadtmauer, E., Kwak, L.W.

Publikováno v: In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e72-e72

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Performance and Symptom Validity Testing in Pediatric Assessment: A Review of the Literature.

Autor: Emhoff, Stephanie M.¹ emhoffst@gmail.com, Lynch, Julie K.², McCaffrey, Robert J.², Emhoff, Stephanie M MA³ (AUTHOR)

Publikováno v: Developmental Neuropsychology. 2018, Vol. 43 Issue 8, p671-707. 37p. 15 Charts.

The high-performance parallel interface (HIPPI) and ultra-speed networks.

Autor: Tolmie, Don E.

Publikováno v: AIP Conference Proceedings; Aug1990, Vol. 209 Issue 1, p528-540, 13p